Cytokinetics Inc

-0.14 (-0.56%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.77B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$6.57 Million
Adjusted EPS-$0.58
See more estimates
10-Day MA$24.22
50-Day MA$22.43
200-Day MA$21.18
See more pivots

Cytokinetics, Inc. Stock, NASDAQ:CYTK

280 East Grand Avenue, South San Francisco, California 94080
Phone: +1.650.624.3000
Number of Employees: 156


Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.